BIOFLOW-III UK Satellite Registry Orsiro Stent System
Study Details
Study Description
Brief Summary
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to long-term complications range from rather immediate elastic coil or vessel contraction to longer processes like smooth muscle cell proliferation and excessive production of extra cellular matrix, thrombus formation and atherosclerotic changes like restenosis or angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to 50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS), designed to address the limitations of PTCA, reduced the angiographic and clinical restenosis rates in De Novo lesions compared to PTCA alone and decreased the need for CABG. BMS substantially reduced the incidence of abrupt artery closure, but restenosis still occurred in about 20 to 40% of cases, necessitating repeat procedures.
The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by adding an antiproliferative drug (directly immobilized on the stent surface or released from a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly reduced the incidence of restenosis and resulted in better safety profile as compared to BMS with systemic drug administration. These advantages and a lower cost compared to surgical interventions has made DES an attractive option to treat coronary artery disease.
Therefore this observational registry has been designed for the clinical evaluation of the ORSIRO LESS requiring coronary revascularization with DES. It is designed to investigate and collect clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting Stent System in an all-comers patient population in daily clinical practice.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Orsiro All subjects requiring coronary revascularization with Drug Eluting Stents (DES) |
Device: Orsiro
|
Outcome Measures
Primary Outcome Measures
- Target Lesion Failure (TLF) [12 months]
Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR)
Secondary Outcome Measures
- TLF [6 months]
Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR)
- Target Vessel Revascularization (TVR) [6 and 12 months]
Any repeat revascularization of the target vessel.
- Target Lesion Revascularization (TLR) [6 and 12 months]
Defined as any repeat revascularization of the target lesion.
- Stent Thrombosis [6 and 12 months]
Definite, Probable and Possible Stent Thrombosis
- Clinical Device Success [up to seven days]
Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without use of a device outside the assigned treatment strategy.
- Clinical Procedural success [up to seven days]
Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without using any adjunctive device without the occurrence of ischemia-driven major adverse cardiac event during the hospital stay to a maximum of the first seven days post index procedure.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Symptomatic coronary artery disease
-
Subject signed informed consent for data release
-
Subject is geographically stable and willing to participate at all follow up assessments
-
Subject is ≥ 18 years of age
Exclusion Criteria:
-
Subject did not sign informed consent for data release
-
Pregnancy
-
Known intolerance to aspirin, clopidogrel, Ticlopidine, heparin or any other anticoagulant/antiplatelet therapy required for PCI, stainless steel, Sirolimus or contrast media
-
Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be maintained
-
Currently participating in another study and primary endpoint not reached yet
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Royal Sussex County Hospital | Brighton | East-Sussex | United Kingdom | BN2 5BE |
| 2 | St Peter's Hospital | Chertsey | Surrey | United Kingdom | KT16 0PZ |
| 3 | University Hospital Southampton | Southampton | United Kingdom | ||
| 4 | Royal Cornwall Hospital | Truro | United Kingdom |
Sponsors and Collaborators
- Biotronik UK Ltd.
Investigators
- Principal Investigator: Michael Mahmoudi, MD, St. Peter's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- G1402